Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study
Keiko Imamura,Yuishin Izumi,Naohiro Egawa,Takashi Ayaki,Makiko Nagai,Kazutoshi Nishiyama,Yasuhiro Watanabe,Takenobu Murakami,Ritsuko Hanajima,Hiroshi Kataoka,Takao Kiriyama,Hitoki Nanaura,Kazuma Sugie,Takehisa Hirayama,Osamu Kano,Masahiro Nakamori,Hirofumi Maruyama,Shotaro Haji,Koji Fujita,Naoki Atsuta,Harutsugu Tatebe,Takahiko Tokuda,Naoto Takahashi,Akiko Morinaga,Riko Tabuchi,Motoki Oe,Mihoko Kobayashi,Kasia Lobello,Satoshi Morita,Gen Sobue,Ryosuke Takahashi,Haruhisa Inoue
DOI: https://doi.org/10.1136/bmjopen-2023-082142
IF: 3.006
2024-10-27
BMJ Open
Abstract:Introduction Amyotrophic lateral sclerosis (ALS) is a progressive, severe neurodegenerative disease caused by motor neuron death. Development of a medicine for ALS is urgently needed, and induced pluripotent cell-based drug repurposing identified a Src/c-Abl inhibitor, bosutinib, as a candidate for molecular targeted therapy of ALS. A phase 1 study confirmed the safety and tolerability of bosutinib in a 12-week treatment of ALS patients. The objectives of this study are to evaluate the efficacy and longer-term safety of bosutinib in ALS patients. Methods and analysis An open-label, multicentre phase 2 study was designed. The study consisted of a 12-week observation period, a 1-week transitional period, a 24-week study treatment period and a 4-week follow-up period. Following the transitional period, patients whose total Revised ALS Functional Rating Scale (ALSFRS-R) score declined by 1 to 4 points during the 12-week observation period were to receive bosutinib for 24 weeks. In this study, 25 ALS patients will be enrolled; patients will be randomly assigned to the following groups: 12 patients in the 200 mg quaque die (QD) group and 13 patients in the 300 mg QD group of bosutinib. The safety and exploratory efficacy of bosutinib in ALS patients for 24 weeks will be assessed. Efficacy using the ALSFRS-R score will be compared with the external published data from an edaravone study (MCI186-19) and registry data from a multicentre ALS cohort study, the Japanese Consortium for Amyotrophic Lateral Sclerosis Research. Ethics and dissemination This study was approved by the ethics committees of Kyoto University, Tokushima University, Kitasato University, Tottori University, Nara Medical University School of Medicine, Toho University and Hiroshima University. The findings will be disseminated in peer-reviewed journals and at scientific conferences. Trial Registration number jRCT2051220002; Pre-results, NCT04744532; Pre-results
medicine, general & internal